NCT01517802View on ClinicalTrials.gov

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 28, 2012

Primary Completion Date

April 22, 2021

Study Completion Date

April 22, 2021

Conditions
Metastatic Castration-resistant Prostate CancerMetastatic Breast Cancer
Interventions
DRUG

Abiraterone acetate

Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily

DRUG

Prednisone

Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily

Trial Locations (22)

Unknown

Aurora

Marrero

Boston

Omaha

East Setauket

New York

Myrtle Beach

Chattanooga

Dallas

Houston

Kogarah

Kurralta Park

South Brisbane

Subiaco

Antwerp

Hamburg

Barcelona

Uppsala

Newcastle upon Tyne

Northwood

Sutton

Whitchurch

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT01517802 - A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate | Biotech Hunter | Biotech Hunter